US FDA approves nintedanib (Ofev) for progressive Interstitial Lung Diseases (ILD)

The FDA has approved nintedanib oral capsules for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype. Nintedanib is currently in phase III development in the EU for this indication.

Source:

US Food and Drug Administration